Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer

This is a phase 3, multicenter, open-label, randomized active-controlled, parallel group to investigate the efficacy, safety and tolerability of intravenous balixafortide given with eribulin versus eribulin alone in the treatment of HER2 negative, Locally Recurrent or Metastatic Breast Cancer.
Breast
Phase III
Adults
Not Available
Not Available
Mayer, Ingrid
National
Vanderbilt University
02-04-2020
Treatment
VICCBRE1947
NCT03786094

Eligibility

Not Available
Not Available
NO
Inclusion Criteria:

Histologically confirmed Breast cancer

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: